From seminal evidence in the early 2000s, the opportunity to drive the specific knockdown of
a protein of interest (POI) through pharmacological entities called Proteolysis Targeting …

Every year, approximately 400 00 children worldwide are diagnosed with cancer. Although
treatment results in most types of childhood neoplasms are excellent with survival more than …

Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients
developing resistance to conventional and targeted therapies. To better understand the …

Simple Summary Aptamers are oligonucleotides that recognise their target with high
specificity and affinity, having properties comparable to those of antibodies; however, they …

Background Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem
duplication (FLT3-ITD) mutation accounts for a large proportion of AML patients and …

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for chronic
myeloid leukemia (CML). However, TKI resistance poses a significant challenge, leading to …

The therapeutic approach to chronic myeloid leukaemia (CML) has changed in recent years.
As a result, a high percentage of current patients in the chronic phase of the disease almost …

Sterile α motif and histidine/aspartic acid domain containing protein 1 (SAMHD1) is a
deoxynucleoside triphosphate (dNTPs) triphosphohydrolase that can hydrolyze dNTPs into …

The efficacy and safety of zanubrutinib, a highly selective next-generation Bruton's tyrosine
kinase (BTK) inhibitor, in chronic lymphocytic leukemia and lymphoplasmocytoides …

Chronic disease is recognized as an illness that takes a long time to develop and never has
a short duration of occurrence they are dangerous to the global community's health (Who & …